Compare Stocks: ESLA, CMPX, SPRB, and OTLK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$0.79 +4.0%	$1.46	$0.73 ▼ $6.88	$136.18M	1.02	4.75 million shs	2.92 million shs
ESLA Estrella Immunopharma	$0.64 -12.3%	$0.58	$0.24 ▼ $3.15	$31.70M	0.93	5.62 million shs	165,669 shs
OTLK Oncobiologics	$0.47 -5.1%	$0.60	$0.16 ▼ $2.54	$120.14M	0.66	4.02 million shs	4.79 million shs
SPRB Spruce Biosciences	$46.39 -0.9%	$50.01	$38.06 ▼ $129.00	$134.56M	3.25	79,133 shs	65,959 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	-0.54%	-5.65%	-31.25%	-60.41%	-79.99%
ESLA Estrella Immunopharma	-11.32%	+0.26%	+58.38%	+2.10%	-70.38%
OTLK Oncobiologics	-9.43%	-12.42%	-21.13%	-49.47%	-61.45%
SPRB Spruce Biosciences	-0.36%	+1.78%	-0.95%	+9.32%	-60.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$0.79 +4.0%	$1.46	$0.73 ▼ $6.88	$136.18M	1.02	4.75 million shs	2.92 million shs
ESLA Estrella Immunopharma	$0.64 -12.3%	$0.58	$0.24 ▼ $3.15	$31.70M	0.93	5.62 million shs	165,669 shs
OTLK Oncobiologics	$0.47 -5.1%	$0.60	$0.16 ▼ $2.54	$120.14M	0.66	4.02 million shs	4.79 million shs
SPRB Spruce Biosciences	$46.39 -0.9%	$50.01	$38.06 ▼ $129.00	$134.56M	3.25	79,133 shs	65,959 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	-0.54%	-5.65%	-31.25%	-60.41%	-79.99%
ESLA Estrella Immunopharma	-11.32%	+0.26%	+58.38%	+2.10%	-70.38%
OTLK Oncobiologics	-9.43%	-12.42%	-21.13%	-49.47%	-61.45%
SPRB Spruce Biosciences	-0.36%	+1.78%	-0.95%	+9.32%	-60.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPX Compass Therapeutics	2.76	Moderate Buy	$10.25	1,203.24% Upside
ESLA Estrella Immunopharma	2.00	Hold	$8.00	1,151.37% Upside
OTLK Oncobiologics	2.20	Hold	$5.20	1,010.87% Upside
SPRB Spruce Biosciences	2.83	Moderate Buy	$158.33	241.31% Upside

Current Analyst Ratings Breakdown

Latest ESLA, CMPX, SPRB, and OTLK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/28/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/15/2026	CMPX Compass Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/13/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/6/2026	SPRB Spruce Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/24/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/24/2026	SPRB Spruce Biosciences	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform	$144.00
9/23/2026	CMPX Compass Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
9/23/2026	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$4.00
9/23/2026	CMPX Compass Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$4.00
9/23/2026	CMPX Compass Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
9/23/2026	CMPX Compass Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Market Outperform	$4.00

(Data available from 10/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPX Compass Therapeutics	$850K	166.64	N/A	N/A	$1.11 per share	0.71
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	($0.27) per share	N/A
OTLK Oncobiologics	-$1.16M	-97.95	N/A	N/A	($0.60) per share	-0.78
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	$39.72 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPX Compass Therapeutics	-$66.49M	-$0.40	N/A	N/A	N/A	N/A	-38.71%	-34.72%	11/4/2026 (Estimated)
ESLA Estrella Immunopharma	-$13.06M	-$0.24	N/A	N/A	N/A	N/A	N/A	-328.72%	12/2/2026 (Estimated)
OTLK Oncobiologics	-$62.42M	-$0.77	N/A	N/A	N/A	N/A	N/A	-254.82%	12/18/2026 (Estimated)
SPRB Spruce Biosciences	-$38.97M	-$39.78	N/A	N/A	N/A	N/A	-123.53%	-90.35%	11/9/2026 (Estimated)

Latest ESLA, CMPX, SPRB, and OTLK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	SPRB Spruce Biosciences	-$5.6756	N/A	N/A	N/A	$50.00 million	N/A
11/4/2026	Q3 2026	CMPX Compass Therapeutics	-$0.12	N/A	N/A	N/A	$0.23 million	N/A
8/14/2026	Q3 2026	OTLK Oncobiologics	-$0.08	-$0.09	-$0.01	-$0.15	$0.97 million	$0.01 million
8/13/2026	Q2 2026	ESLA Estrella Immunopharma	-$0.09	-$0.05	+$0.04	-$0.05	N/A	N/A
8/12/2026	Q2 2026	SPRB Spruce Biosciences	-$5.79	-$6.68	-$0.89	-$6.68	N/A	N/A
8/6/2026	Q2 2026	CMPX Compass Therapeutics	-$0.1107	-$0.13	-$0.0193	-$0.13	($0.60) million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPX Compass Therapeutics	N/A	11.22	11.22
ESLA Estrella Immunopharma	N/A	0.20	0.20
OTLK Oncobiologics	N/A	0.81	0.63
SPRB Spruce Biosciences	0.05	9.23	9.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPX Compass Therapeutics	68.43%
ESLA Estrella Immunopharma	0.35%
OTLK Oncobiologics	11.20%
SPRB Spruce Biosciences	91.71%

Insider Ownership

Company	Insider Ownership
CMPX Compass Therapeutics	18.70%
ESLA Estrella Immunopharma	5.80%
OTLK Oncobiologics	1.80%
SPRB Spruce Biosciences	4.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPX Compass Therapeutics	39	180.09 million	146.41 million	Optionable
ESLA Estrella Immunopharma	3	43.50 million	40.98 million	Not Optionable
OTLK Oncobiologics	17	243.45 million	239.07 million	Optionable
SPRB Spruce Biosciences	8	2.87 million	2.75 million	Optionable

ESLA, CMPX, SPRB, and OTLK Headlines

Recent News About These Companies

Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference

October 15, 2026 | finance.yahoo.com

Spruce Biosciences, Inc. (NASDAQ:SPRB) Stock Rated "Moderate Buy" by Wall Street Analysts

October 13, 2026 | marketbeat.com

Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting

October 8, 2026 | financialpost.comF

Analysts Are Bullish on These Healthcare Stocks: Spruce Biosciences (SPRB), Arcus Biosciences (RCUS)

October 3, 2026 | theglobeandmail.com

Spruce Biosciences (SPRB) Reiterated at Market Outperform by Citizens on TA-ERT Therapy Lead

September 24, 2026 | streetinsider.com

Lake Street initiates coverage of Spruce Biosciences at buy

September 18, 2026 | msn.com

Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | businesswire.com

Oppenheimer Sticks to Its Buy Rating for Spruce Biosciences (SPRB)

August 28, 2026 | theglobeandmail.com

Spruce Biosciences stock gains after analyst backs regulatory progress

August 27, 2026 | finance.yahoo.com

Spruce Biosciences Announces Launch of MPS3BStudy.com

August 26, 2026 | finance.yahoo.com

Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026

August 24, 2026 | finance.yahoo.com

Spruce Biosciences Inc.

August 16, 2026 | marketwatch.com

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

August 12, 2026 | aol.comA

Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences

August 12, 2026 | finance.yahoo.com

Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development

August 3, 2026 | finance.yahoo.com

Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer

July 27, 2026 | finance.yahoo.com

Spruce Biosciences Names Adrian Quartel Chief Medical Officer

July 27, 2026 | tipranks.com

Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

July 8, 2026 | finance.yahoo.com

Spruce Biosciences Possibly First In-MPS IIIB Class Enzyme Replacement Therapy

July 8, 2026 | seekingalpha.com

Spruce Biosciences Joins the Russell 3000® Index

June 29, 2026 | finance.yahoo.com

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

June 15, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ESLA, CMPX, SPRB, and OTLK Company Descriptions

Compass Therapeutics NASDAQ:CMPX

$0.79 +0.03 (+4.01%)

Closing price 04:00 PM Eastern

Extended Trading

$0.79 +0.00 (+0.45%)

As of 07:52 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Estrella Immunopharma NASDAQ:ESLA

$0.64 -0.09 (-12.27%)

Closing price 04:00 PM Eastern

Extended Trading

$0.65 +0.01 (+1.36%)

As of 06:49 PM Eastern

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Oncobiologics NASDAQ:OTLK

$0.47 -0.03 (-5.15%)

Closing price 04:00 PM Eastern

Extended Trading

$0.47 +0.00 (+0.19%)

As of 07:59 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Spruce Biosciences NASDAQ:SPRB

$46.39 -0.43 (-0.92%)

Closing price 04:00 PM Eastern

Extended Trading

$46.44 +0.05 (+0.10%)

As of 07:30 PM Eastern

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ESLA, CMPX, SPRB, and OTLK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ESLA, CMPX, SPRB, and OTLK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ESLA, CMPX, SPRB, and OTLK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ESLA, CMPX, SPRB, and OTLK Company Descriptions

Compass Therapeutics NASDAQ:CMPX

Estrella Immunopharma NASDAQ:ESLA

Oncobiologics NASDAQ:OTLK

Spruce Biosciences NASDAQ:SPRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ESLA, CMPX, SPRB, and OTLK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ESLA, CMPX, SPRB, and OTLK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ESLA, CMPX, SPRB, and OTLK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ESLA, CMPX, SPRB, and OTLK Company Descriptions

Compass Therapeutics NASDAQ:CMPX

Estrella Immunopharma NASDAQ:ESLA

Oncobiologics NASDAQ:OTLK

Spruce Biosciences NASDAQ:SPRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools